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to ≥ 3 groups which initiate double-blind active therapy at different times from 
baseline, preceded by 0,1, 2 or more intervals of placebo. Analytical and simulation-
based investigations were conducted to compare the statistical power, required 
assumptions, practical considerations and economic features of the Blind Start to 
conventional single-arm and randomized designs. Results: Given the same num-
ber of patients, the randomized Blind Start provides equivalent statistical power for 
detecting changes pre- vs. post-treatment compared to a conventional single-arm 
design. However, by concealing treatment initiation times, the Blind Start enables 
more objective assessments of outcomes that are effort-based, patient-reported 
or subjectively assessed by investigators. In addition, compared to a conventional 
2-arm randomized trial, analysis of parallel treatment and placebo groups embed-
ded within a Blind Start design provides greater power to detect treatment effects 
over any fixed time interval. For example, with N= 16 and a treatment effect equal 
to 1 standard deviation of the outcome measure, a 4-arm Blind Start design provides 
85% power in a pre-post analysis and 79% power in an analysis of embedded paral-
lel groups. In contrast, a conventional 2-arm randomized trial provides 52% power 
in this scenario. Benefits of the Blind Start design come at the expense of 1) more 
patient-time in the trial and 2) lack of stringent control over patient status upon 
active treatment initiation. ConClusions: The randomized Blind Start design can 
improve precision for treatment effect estimation vs. parallel-group designs and 
reduce risk of bias vs. single-arm designs. Endpoint choice and statistical analysis 
strategies for the Blind Start design can maximize the assessment of treatment 
effects on multiple outcomes.
RESEARCH on MEtHodS – Study design
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objeCtives: The economic evaluation of health care interventions is now an 
accepted element of health care decision-making and priority-setting. As the num-
ber of published economic evaluations has grown, so has the number of systematic 
reviews of economic evaluations. However, the quality of search methodology used in 
recent reviews has not been widely investigated. This study sought to identify which 
search resources are being used to identify studies in recent, published systematic 
reviews of economic evaluations, and to investigate whether choice of resources 
reflects current recommendations for the conduct of such reviews. Methods: 
A search to identify systematic reviews of economic evaluations published since 
January 2013 was undertaken in MEDLINE. Two reviewers extracted the following 
information from reviews which met the inclusion criteria: general medical litera-
ture databases searched, specialist economic databases searched, health technology 
assessment sources searched, supplementary search techniques used. Results were 
compared against the search resources recommended by NICE when searching for 
economic evidence for single technology appraisals, and the summary of current 
best evidence provided in Sure Info (http://vortal.htai.org/?q= node/336). Results: 
Sixty-five systematic reviews met the inclusion criteria; 23 of these could not be 
accessed in full text, data was extracted from 42 reviews. Five reviews (12%) met 
or exceeded the search resources recommended by NICE (MEDLINE, Embase, NHS 
EED, EconLit). Nine reviews (21%) searched at least four of the six types of resource 
recommended by Sure Info (specialist economic databases, general databases, HTA 
databases, webpages of HTA agencies, grey literature, collections of utility studies). 
None of the reviews searched all six. Although all reviews explicitly described the 
resources searched, reporting frequently contained errors or lack of clarity in the 
names of databases and interfaces. ConClusions: The information resources used 
to identify evidence for the majority of recently published systematic reviews of 
economic evaluations do not conform to current recommendations.
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objeCtives: Retrospective database studies rely on the ability to accurately iden-
tify patient cohorts of interest within health care databases. Diagnosis code-based 
algorithms are the primary method of identifying patient cohorts; however, many 
databases lack reliable diagnosis code information. Our aim was to develop precise 
algorithms based on medication claims/prescriber visit (MC/PV) to identify psoriasis 
(PsO) patients or psoriatic patients with arthritic conditions (PsO-AC), a proxy for 
psoriatic arthritis, in databases lacking diagnosis codes. Methods: Algorithms 
were developed using medications with narrow indication profiles in combina-
tion with prescriber specialty to define PsO and PsO-AC. For the study period of 
July 1, 2009 to June 30, 2013, algorithms were validated using the PharMetrics Plus™ 
(PharMetrics) database, which contains both adjudicated medication claims and 
diagnosis codes. Positive predictive value (PPV), negative predictive value (NPV), sen-
sitivity and specificity of algorithms developed for PsO and PsO-AC were assessed 
using diagnosis code as the reference standard. Results: In the PharMetrics data-
base, 183,328 patients were identified by diagnosis code or medication claim for vali-
dation. The highest PPVs for PsO (85%) and PsO-AC (65%) occurred when a predictive 
algorithm of ≥ 2 MC/PVs was compared to the reference standard of ≥ 1 diagnosis 
code. The majority of PsO-AC false positives had a diagnosis of PsO and pain or joint 
symptoms. NPV and specificity were also high (99 – 100%), while sensitivity was low 
(≤ 30%). Reducing the number of MC/PVs or increasing diagnosis claims decreased 
in type 2 diabetes mellitus. Comprehension of the checklist was assessed based 
on qualitative interviews of each analyst. A measure of the inter-analysts agree-
ment was estimated to ensure the reliability of the checklist. Results: Checklists 
identified from the literature included the checklist developed by the NICE Decision 
Support Unit and the one developed by the ISPOR task force. These two checklists 
were developed for analysts who conduct NMAs as well as analysts who critically 
review NMAs. However, they seem to lack clarity for non-statisticians. We developed 
a new checklist, which included the following items: definition of the study question 
(list of comparators, study population), methods (study selection, data extraction, 
statistical model, selection of fixed versus random effects model, assumptions for 
the base case, heterogeneity and inconsistency assessment and sensitivity analy-
ses), reporting of results (network and source data, median or mean and 95% cred-
ibility interval) and interpretation of results. ConClusions: Our checklist can be 
used by analysts not trained in statistics to prepare or review NMAs to be submitted 
to NICE and/or to populate cost-effectiveness models.
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objeCtives: This work aims to develop a methodology for determining the qualita-
tive composition of an expert group for the purpose of participation in decision-
making in health care technology. Its goal is also to evaluate the methodology 
based on an example of the selection of large medical equipment. Methods: The 
complex weighting factor is a comprehensive evaluation of an expert. It is based 
on the expert’s overall work experience, experience in solving tasks, level of educa-
tion and scientific record, interest in solving the particular task, current position, 
and awareness of how to solve the task. Also taken into account are the relevance 
of the expert’s knowledge and the overall self-evaluation concerning his or her 
total competence in solving the task. For the purpose of validating the method-
ology, 96 potential experts were interviewed. These subjects included managers 
from relevant departments in hospitals and hospital staff members who were from 
72 health facilities in the Czech Republic. Results: Unlike the other models, the 
calculation model that was selected is able to eliminate errors in estimating the 
proportionality of extreme values and to reduce the impact of uncertainty in the 
experts’ overall self-evaluations concerning their total competence to the combined 
ratio. Based on this model, a methodology for selecting experts was developed. A 
statistically significant correlation was found between the complex weighting factor 
and the following characteristics: the expert’s experience in dealing with similar 
tasks (r= 0.512, p< 0.001), the expert’s theoretical background (awareness) and the 
relevance of the expert’s knowledge (r= 0.44, p< 0.001), the expert´s current position 
(r= 0.319, p= 0.002), and the level of his or her education and scientific record (r= 0.28, 
p= 0.007). ConClusions: This methodology will be especially useful in scientific 
and technological forecasting, medical and managerial decision-making, quality 
assessment, and operational research.
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objeCtives: To evaluate treatment effect on longitudinal patient-reported out-
comes using appropriate analytical strategy. Methods: This was an ad-hoc analy-
sis of longitudinal patient-reported outcomes using a two stages simulated data 
in which the true model is known, to explore and to evaluate the capability of the 
group-based trajectory method to identify the distinctive features of a highly irregu-
lar but still continuous population distribution of trajectories. Firstly, we created 
six different types of underlying trajectory in which the true model is known and 
added in level-one between occasion random noises. Then we added a level-two, 
between- patients variation (of the random intercept form) with differing variabil-
ity to each of the six distinctive trends. This simulation allows us to examine how 
the software implementation identifies different group trajectories as well as their 
level-one and -two variances. It was recognized that a priori assignment of distinct 
longitudinal trajectories may not be appropriate and that no ability to calibrate 
the precision of individual classifications exists if ex-ante rules are used. Thus, 
latent group-based trajectory model, a method to map the developmental course of 
symptoms and assess heterogeneity in response to clinical interventions, was used 
to identify patient groups with varied response. Results: The fitted trajectories 
closely approximate the true shapes and there is also a close correspondence for the 
percentage of places attributed to each group. Even the size of the level 1 random 
term is correctly estimated. The semi-parametric group-based trajectory method 
has demonstrated unequivocally its capability to capture the unobserved subgroups 
in the presence of considerable level-1 random variation. ConClusions: Patients 
in many disease areas experience changes in QoL in different ways. Identification 
of those groups is essential for appropriate evaluation of therapy treatment effects 
and identification of factors contributing to those groupings.
PRM211
tHE RAndoMizEd blind StARt tRiAl: EvAluAtion of A nEw Study 
dESign foR ASSESSing CliniCAl outCoMES in RARE And HEtERogEnEouS 
PAtiEnt PoPulAtionS
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objeCtives: Clinical development of therapies for rare diseases can benefit from 
improvements to conventional trial designs. This study evaluated a new trial design, 
the randomized Blind Start. Methods: The Blind Start design randomizes patients 
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getting a positive final test result (i.e. wrongly continued). The developed software 
(i.e. R-codes) can easily be applied to other cases.
PRM218
nEgAtivE REiMbuRSEMEnt ConSEQuEnCES fRoM tRiAl dESign CHoiCES
Jaksa A., Westbrook L., Daniel K., Ho Y.S.
Context Matters, Inc., New York, NY, USA
objeCtives: Health Technology Assessments (HTA) use clinical trial data to deter-
mine comparative efficacy and cost-effectiveness; thus study design plays a roll 
in market access. The objective is to determine how often reimbursement deci-
sions cite trial design defects. Methods: We analyzed 1,702 HTAs from CADTH, 
G-BA, HAS, NICE, PBAC, and SMC. We examined the clinical assessment rationale 
for the decision and the reimbursement decisions. An explicit trial design defect 
was defined as a clinical assessment of “inappropriate comparator” or “inappro-
priate patient population.” Clinical assessments of lower, uncertain, or unknown 
efficacy or a clinical determination of insufficient or lack of evidence were defined 
as potential trial design defects. Results: Reviews that cited trial defects resulted 
in significantly more negative reimbursement decisions (6.6%) than positive reim-
bursement decisions (0.4%; p< .001). This pattern held true for each individual 
agency examined. G-BA was the agency most likely to cite an explicit trial deficit 
(39%), while HAS was the least likely (0.6%). In addition, significantly more reviews 
that cited a potential trial defect resulted in negative reimbursement decisions (44%) 
than positive reimbursement decisions (5.5%; p< .001). This also held true for each 
agency. Again, G-BA was most likely to note a potential trial defect in reviews (46%) 
while SMC was least likely (6.4%). Among disease conditions with more than 10 
reviews, explicitly cited trial defects were mostly frequently seen in Cystic Fibrosis 
and Parkinson’s Disease (15% and 13%, respectively). Potential trial defects were 
most frequently cited in Atrial Fibrillation and Depression reviews (42% and 39% 
respectively). ConClusions: Explicit and potential trial design issues have nega-
tive consequences for reimbursement outcomes. Negative decisions are more likely 
than positive decisions to cite trial design issues. G-BA is more inclined than other 
agencies to cite these trial design issues when issuing their reimbursement deci-
sions. Manufacturers should consider market-access outcomes when designing 
clinical trials.
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MEdiCAtion uSE: PERi-APPRovAl APPRoxiMAtion of PoSt-MARkEt 
PRACtiCE PAttERnS And CoStS
Stein D.1, Jean-Mary J.2, Goldwin A.E.2, Lau M.R.3, Manson S.3
1UBC: An Express Scripts Company, Dorval, QC, Canada, 2United BioSource Corporation, London, 
UK, 3GlaxoSmithKline Oncology, Uxbridge, UK
objeCtives: Compassionate use programmes provide peri-approval drug access 
based on unsolicited physician requests for patients with unmet need. Practice 
pattern evaluations in this context, using chart review methodology, permits the 
collection of pre-approval data outside of clinical trial settings that can approxi-
mate real-world post-market use. Data can be used to inform important economic 
evaluations, value dossiers, and drug safety assessments. Methods: Study design 
and operational considerations related to chart review studies of compassionate 
use populations have been summarized by evaluating three multi-national case 
studies. Results: The source populations of patients were drawn from compas-
sionate use programmes providing oral anti-cancer therapies. These were initi-
ated pre-approval following positive clinical trial findings. Countries included 
Australia, Belgium, Greece, Ireland, Israel, Italy, The Netherlands, New Zealand, 
Spain, Switzerland and the United Kingdom. Data including patient character-
istics, patterns of care and drug dosing, duration of treatment and reasons for 
treatment discontinuation, overall survival, clinical benefit, progression free sur-
vival and adverse and serious adverse events are being collected to inform health 
economic and other burden of illness assessments. Site and patient selection was 
performed using compassionate use enrollment data, facilitating an efficient study 
start-up. Data were cleaned at point of data entry and via an electronic query pro-
cess in real-time resulting in tailored international datasets. Patients provided con-
sent for their medical data to be used prior to initiating compassionate use therapy, 
and additional ethical approval for the chart review was sought on a local and/
or national level. Chart review study design requires a balance between scientific 
and operational rigor and practicality and feasibility. ConClusions: Peri-approval 
chart review studies of patients in compassionate use programmes offer an impor-
tant opportunity to characterize patterns of use and associated treatment costs as 
well as the clinical impact of investigational medications in non-trial settings to 
inform clinical, health economic and market access decisions.
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objeCtives: Scientific research suggests that randomized controlled trials ter-
minated early for benefit considerations systematically overestimate treatment 
effects of the primary outcome. This study assessed whether Health Technology 
Assessment (HTA) agencies accept the increased uncertainty around overall survival 
(OS) estimates in oncology trials arising from early termination. Methods: Public 
scientific databases were searched to identify scientific articles and pivotal trials 
involving early trial termination. A selection of related HTA appraisals, published 
between January 2011 and February 2014, were analysed. Current scientific evidence 
on the impact of early stopping on outcome estimates was compared to the conclu-
sions made by 11 HTA agencies. Results: Twelve scientific articles, 12 pivotal trials, 
and 31 related HTA appraisals were selected for in-depth analysis. The scientific 
literature suggests that more stringent significance levels in the repeated interim 
the algorithms’ PPV. ConClusions: We have demonstrated that MC/PV algorithms 
can be used to identify PsO patients with a high degree of accuracy, while PsO-AC 
accuracy requires further investigation. Such methods allow researchers to conduct 
retrospective studies in databases where diagnosis codes are absent.
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objeCtives: The nested case-control (NCC) design offers a simple method for 
avoiding unreasonable assumptions in the evaluation of time-dependent treat-
ment effect. Its results are easy to interpret. Its strength rests largely on the appro-
priateness of the controls which are matched to the cases- suggesting a matching 
strategy that ensures maximum number of discordant case-control pairs may be 
more efficient since effect estimation is based entirely on the off-diagonal data of 
the resulting 2x2 tables in the conditional logistic regression. In theory, the more 
off-diagonal pairs that are generated by the random sampling scheme, the more 
improvement we can expect on efficiency. The objective of this study is to assess the 
efficiency of counter-matching on treatment compared with the classical matching 
approach in the NCC design based on results from the cohort design using simulated 
data. Methods: In each simulation of 1000 patients at 100 replications per run, we 
assumed an underlying event hazard of Weibull distribution using inputted values 
for the scale and shape parameters, treatment, age and sex as the factors. Each 
run involved distinct treatment prevalence of between 10%-50% with event rate 
varying from common to very rare. We compared the proportion of matched pairs 
(at 1 control per case) used in the analyses of the resulting data between the classi-
cal and counter matching strategies. Results: The counter-matched strategy was 
more efficient than the classical approach. The proportion of matched pairs used 
was on average over ten times more and it also gave mean effect estimates which 
were more consistent with the full cohort values, particularly for low treatment 
exposure and rare events. ConClusions: Our results suggest counter matching is 
more efficient and more accurate estimates than classical matching in nested case-
control design. These benefits may be particularly important for studies involving 
rare events or low treatment exposure.
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objeCtives: To assess the methodological quality of randomized controlled trials 
(RCTs) published in “Russian Allergology Journal” (RAJ) in 2009-2013. Methods: 
Retrospective analysis of 96 original publications was carried out. For 8 RCT the 
risks of biases were assessed using the methodology of the Cochrane Collaboration. 
Accuracy of statistical analysis was assessed in accordance with established in 
2009 journal’s requirements, made in accordance with best international prac-
tice. Results: 96 articles were analysed, 8 (8%) of them were identified as RCTs. All 
the RCTs have a high risk of the biases and major mistakes in the statistical analy-
sis. ConClusions: The methodological quality of RCTs is insufficient and needs 
to be improved. We consider that the most important role should play improvement 
of trials’ planning. Collaboration with the experts in clinical trials’ methodology 
is strongly recommended. The analysis empowers researchers to consider exist-
ing experience and to improve methodological quality of RCTs, their relevance to 
international standards.
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objeCtives: A head-to-head randomized clinical trial (RCT) to evaluate a new 
drug is financially risky, because a positive outcome is uncertain. We simulate 
and evaluate a head-to-head RCT design incorporating an additional go/no-go 
efficacy interim analysis to show the consequences of this additional interim anal-
ysis. Methods: We simulate the endpoint event-free-survival (EFS) of patients 
in a head-to-head RCT. The decision rule of the additional interim efficacy analy-
sis (i.e. stop or continue) depends on the number of patients (i.e. 300,400 or 500 
patients) and the significance level (i.e. α = 0.05, α = 0.10 or α = 0.20) of the interim 
analysis. The RCT without an interim-analysis has significance level α = 0.05, 
power= 0.86 and sample size 800. Results: Each combination of sample size 
and significance level, which is called a scenario, is investigated by simulating 
2,000 trials of 800 patients. Per simulated scenario we report, among others, the 
“Probability of positive final analysis test result GIVEN negative interim analysis 
test result” (= wrongly stopped) and the “Probability of negative final analysis 
test result GIVEN positive interim analysis test result” (= wrongly continued). 
The results of the first scenario, i.e. an interim analysis at 300 included patients 
and significance level α = 0.05, are as follows. If the actual improvement of the EFS 
hazard rate is 0%, the abovementioned probabilities are 3.65% and 7.85%. An actual 
improvement effect of 5% changes the probability values to 20.25% and 12.80, 
while an actual improvement effect of 10% causes the probability values 28.50% 
and 5.55%. ConClusions: The simulated probabilities were mainly influenced 
by the actual EFS improvement. The smaller the actual outcome improvement, the 
greater the probability of continuing the trial up to 800 included patients without 
